MedTrace Logo

Remicade Infusion Management Program

NCT00723905 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1630

Last updated 2013-01-15

No results posted yet for this study

Summary

Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.

Conditions

  • Crohn Disease
  • Arthritis, Rheumatoid

Sponsors & Collaborators

  • Janssen Inc.

    lead INDUSTRY

Principal Investigators

  • Janssen Inc. Clinical Trial · Janssen Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00723905 on ClinicalTrials.gov